EUCTR2006-005981-37-DK进行中（未招募）不适用
Behandling af sekundær hyperparathyreoidisme hos uræmiske patienter.En sammenlignenede undersøgelse mellem virkningen af alfacalcidol og paricalcitol.
Roskilde Amts Sygehus0 个研究点开始时间: 2006年11月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Age >18 years
- •b. Sekundary hyperparathyreoidism (iPTH > 350 pg/ml )without treatment or after a break of vitamin D treatment of min. 6 weeks.
- •c. Chronic uremia in hæmodialysis.
- •d. P-fosfat < 1,8 mmol/l
- •e. P-calciumion < 1,25 mmol/l
- •f. Recieving maximal dose of calciumcontaining fosfatbinder.
- •g. Accepting 2 x 6 weeks without D-vitamin treatment.
- •h. Safe antikonception for women in fertile age and negativ pregnancy-test before inklusion.
- •i. Need of calcimimetics or parathyroidektomi is not expected during the following year.
- •j. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Diagnosed malign disease.
- •b. Diseases or conditions making the patient unable to participate.
- •c. Expected survival less than one year.
- •d. Pregnancy and nursing.
- •e. Allergic to contents in the medications.
- •f. In treatment with calcimimetics
- •g. Participating in other intervention studies wich can affect endpoints of the study.
研究者
相似试验
已完成
4 期
The comparison of calcimimeticsChronic kidney diseaseJPRN-jRCTs051190014Kuragano Takahiro300
尚未招募
不适用
On target management for secondary hyperparathyroidism by two calcimimetics (HP2C study)Chronic kidney diseaseJPRN-UMIN000029000Hyogo College of Medicine300
进行中（未招募）
不适用
TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET - NDPrimary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)MedDRA version: 9.1Level: LLTClassification code 10027180EUCTR2008-005055-23-ITOSPEDALE MAGGIORE DI MILANO (IRCCS)
进行中（未招募）
1 期
Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing?MedDRA version: 14.1Level: LLTClassification code 10041597Term: Spinal stenosis of lumbar regionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSpinal stenosisEUCTR2011-006152-36-DKMiddelfart Rygsektor100
招募中
2 期
Treatment of a Thyroid (Hypothyroidism) with gomutra haritaki tabletCTRI/2017/09/009868Ritu Sheoran30